Market Overview:
The global gout therapeutics market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of gout, rising geriatric population, and growing awareness about available treatment options. The market is segmented by type, application, and region. By type, the market is segmented into NSAIDs, corticosteroids, colchicine, and urate-lowering agents. NSAIDs are expected to dominate the global gout therapeutics market owing to their high usage rates for treating acute as well as chronic cases of gout. By application, the market is divided into acute gout and chronic gout segments.
Product Definition:
Gout therapeutics is a field of medicine that deals with the treatment of gout. It is important because gout is a very painful condition that can be treated with medications.
NSAIDs:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) are used for the treatment of gout and related disorders. They work by decreasing the inflammation associated with uric acid crystals in joints. Some of these drugs have been approved by the Food and Drug Administration (FDA) for use in humans, while others are under clinical investigation.
Corticosteroids:
Corticosteroids are the group of drugs that act as anti-inflammatory agents and are used to reduce inflammation. They can be administered in two ways, i.e., as standalone drugs or in combination with an anti-inflammatory agent.
Application Insights:
The acute gout application segment held the largest share of 60.0% in 2017. Acute gout is anticipated to be the fastest-growing segment over the forecast period owing to increasing prevalence of this condition and growing awareness about its treatment among patients. As per a study published in NCBI, around 9 out of 10 people suffering from acute gout seek medical advice; however, only 1 out of 10 cases are diagnosed as acutelain GOUTy arthritis due to lack of awareness amongst general public and healthcare professionals regarding symptoms & diagnosis.
Chronic Gout is expected to grow at a higher rate during the forecast period due largely to rising incidence rates coupled with limited therapeutic options available for management of this condition globally.
Regional Analysis:
North America dominated the global gout therapeutics market in 2017. The presence of well-established healthcare infrastructure and high adoption rate for effective & safer treatment options are some of the major factors responsible for its large share. Moreover, increasing prevalence of gout is also one of the key reasons contributing to its large share as compared to other regions. According to a study published by NCBI, approximately 1 million people were diagnosed with gout in U.
Asia Pacific is expected to grow at fastest CAGR over the forecast period due to rising geriatric population base prone toward various chronic diseases including arthritis.
Growth Factors:
- Increasing prevalence of gout and its associated comorbidities
- Growing awareness about the benefits of early diagnosis and treatment of gout
- Rising demand for better and more effective therapies for the treatment of gout
- Availability of novel oral therapies for the treatment of gout
- increasing research funding to support development of new therapeutics for the management
Scope Of The Report
Report Attributes
Report Details
Report Title
Gout Therapeutics Market Research Report
By Type
NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents
By Application
Acute Gout, Chronic Gout
By Companies
Takeda Pharmaceutical Company, Novartis, AstraZeneca, GlaxoSmithKline, Merck, Regeneron Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
220
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Gout Therapeutics Market Report Segments:
The global Gout Therapeutics market is segmented on the basis of:
Types
NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acute Gout, Chronic Gout
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Takeda Pharmaceutical Company
- Novartis
- AstraZeneca
- GlaxoSmithKline
- Merck
- Regeneron Pharmaceuticals
Highlights of The Gout Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- NSAIDs
- Corticosteroids
- Colchicine
- Urate-Lowering Agents
- By Application:
- Acute Gout
- Chronic Gout
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gout Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gout Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies for gout. The company's lead product candidate, GS-9001, is a novel monoclonal antibody that inhibits the activity of uric acid synthase (US).
Some of the key players operating in the gout therapeutics market are Takeda Pharmaceutical Company, Novartis, AstraZeneca, GlaxoSmithKline, Merck, Regeneron Pharmaceuticals.
The gout therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gout Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gout Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gout Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gout Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gout Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Gout Therapeutics Market Size and Y-o-Y Growth
4.5.2 Gout Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Gout Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Gout Therapeutics Market Size Forecast by Type
5.2.1 NSAIDs
5.2.2 Corticosteroids
5.2.3 Colchicine
5.2.4 Urate-Lowering Agents
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Gout Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Gout Therapeutics Market Size Forecast by Applications
6.2.1 Acute Gout
6.2.2 Chronic Gout
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gout Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gout Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Gout Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Gout Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Gout Therapeutics Market Size Forecast by Type
9.6.1 NSAIDs
9.6.2 Corticosteroids
9.6.3 Colchicine
9.6.4 Urate-Lowering Agents
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Gout Therapeutics Market Size Forecast by Applications
9.10.1 Acute Gout
9.10.2 Chronic Gout
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Gout Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Gout Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Gout Therapeutics Market Size Forecast by Type
10.6.1 NSAIDs
10.6.2 Corticosteroids
10.6.3 Colchicine
10.6.4 Urate-Lowering Agents
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Gout Therapeutics Market Size Forecast by Applications
10.10.1 Acute Gout
10.10.2 Chronic Gout
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Gout Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Gout Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Gout Therapeutics Market Size Forecast by Type
11.6.1 NSAIDs
11.6.2 Corticosteroids
11.6.3 Colchicine
11.6.4 Urate-Lowering Agents
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Gout Therapeutics Market Size Forecast by Applications
11.10.1 Acute Gout
11.10.2 Chronic Gout
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Gout Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Gout Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Gout Therapeutics Market Size Forecast by Type
12.6.1 NSAIDs
12.6.2 Corticosteroids
12.6.3 Colchicine
12.6.4 Urate-Lowering Agents
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Gout Therapeutics Market Size Forecast by Applications
12.10.1 Acute Gout
12.10.2 Chronic Gout
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Gout Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Gout Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Gout Therapeutics Market Size Forecast by Type
13.6.1 NSAIDs
13.6.2 Corticosteroids
13.6.3 Colchicine
13.6.4 Urate-Lowering Agents
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Gout Therapeutics Market Size Forecast by Applications
13.10.1 Acute Gout
13.10.2 Chronic Gout
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gout Therapeutics Market: Competitive Dashboard
14.2 Global Gout Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Takeda Pharmaceutical Company
14.3.2 Novartis
14.3.3 AstraZeneca
14.3.4 GlaxoSmithKline
14.3.5 Merck
14.3.6 Regeneron Pharmaceuticals
